These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 14574440)
1. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Ingelman-Sundberg M Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):89-104. PubMed ID: 14574440 [TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Bozina N; Bradamante V; Lovrić M Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of the major polymorphic metabolizing enzymes. Daly AK Fundam Clin Pharmacol; 2003 Feb; 17(1):27-41. PubMed ID: 12588628 [TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Gong L; Zhang CM; Lv JF; Zhou HH; Fan L Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962 [TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Manikandan P; Nagini S Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. Foti RS; Dalvie DK Drug Metab Dispos; 2016 Aug; 44(8):1229-45. PubMed ID: 27298339 [TBL] [Abstract][Full Text] [Related]
8. Polymorphism of cytochrome P450 and xenobiotic toxicity. Ingelman-Sundberg M Toxicology; 2002 Dec; 181-182():447-52. PubMed ID: 12505350 [TBL] [Abstract][Full Text] [Related]
9. Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome. Niwa T; Murayama N; Yamazaki H Curr Drug Metab; 2009 Sep; 10(7):700-12. PubMed ID: 19594405 [TBL] [Abstract][Full Text] [Related]
10. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Lee IS; Kim D Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682 [TBL] [Abstract][Full Text] [Related]
11. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF; Liu JP; Chowbay B Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967 [TBL] [Abstract][Full Text] [Related]
12. Genetic variability in susceptibility and response to toxicants. Ingelman-Sundberg M Toxicol Lett; 2001 Mar; 120(1-3):259-68. PubMed ID: 11323184 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450]. Saldaña-Cruz AM; Sánchez-Corona J; Márquez de Santiago DA; García-Zapién AG; Flores-Martínez SE Rev Neurol; 2013 May; 56(9):471-9. PubMed ID: 23629749 [TBL] [Abstract][Full Text] [Related]
14. Steroid regulation of drug-metabolizing cytochromes P450. Monostory K; Dvorak Z Curr Drug Metab; 2011 Feb; 12(2):154-72. PubMed ID: 21395541 [TBL] [Abstract][Full Text] [Related]
17. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Hart SN; Zhong XB Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Oscarson M Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605 [TBL] [Abstract][Full Text] [Related]
19. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Naidoo P; Chetty VV; Chetty M Eur J Clin Pharmacol; 2014 Apr; 70(4):379-89. PubMed ID: 24390631 [TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications. Cederbaum AI Redox Biol; 2015; 4():60-73. PubMed ID: 25498968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]